Apremilast in plaque psoriasis: A retrospective, real-life study up to 12-month observation
Background: Apremilast is an oral phosphodiesterase 4 inhibitor approved for treatment of psoriasis and psoriatic arthritis (PsAs). The aim of this study was to evaluate the efficacy and safety of apremilast in a real-life cohort of patients with plaque psoriasis.
Source: Journal of the American Academy of Dermatology - Category: Dermatology Source Type: research
More News: Academies | Arthritis | Dermatology | Psoriasis | Psoriatic Arthritis | Rheumatology | Skin | Study